| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.45 | 0.1 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.4 | 0.05 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.36 | 0.1 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.35 | 0.009 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.32 | 0.02 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.3 | 0.03 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.29 | 0.3 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.23 | 7e-05 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.22 | 8e-09 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.22 | 0.0002 |